Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro.
CD56(pos) natural killer (NK)/natural T (NT) cells are important innate effectors providing the first line of defense against viral infection. Enhanced NK activity has been shown to protect from human immunodeficiency virus-1 infection. However, the role played by these innate effectors in protection against or development of hepatitis C virus (HCV) infection is unknown. We characterized CD56(pos) populations in 11 injection drug users (IDUs) who remained uninfected despite being repeatedly exposed to HCV. NK profiles in exposed but uninfected (EU) individuals were compared with preinfection samples (median 90 days prior to HCV seroconversion) collected from 14 IDUs who were exposed and subsequently became infected (EI) and unexposed normal control subjects (n = 8). Flow cytometric analysis of CD56(pos) populations demonstrated that EUs had a higher proportion of CD56(low) mature (P = 0.0011) NK cells compared with EI subjects. Bead-isolated NKs ( > 90% purity) from EUs had significantly higher interleukin-2 (IL-2)-induced cytolytic activity against the NK-sensitive cell line K562 at an effector-to-target ratio of 10:1 (P < 0.0001). NKp30, a natural cytotoxicity receptor involved in NK activation, is highest on NK/NT cells in EUs relative to infected subjects. Using the JFH-1 infection system, we demonstrated that NKp30(high) cells in the absence of exogenous stimulation significantly reduce infection of hepatocytes.


CONCLUSIONS
CD56(pos) populations in EUs are enriched for effector NKs displaying enhanced IL-2-induced cytolytic activity and higher levels of the natural cytotoxicity receptor NKp30-activating receptor. In addition, NKp30(high) cells are more effective in preventing infection of Huh-7.5 cells than their NKp30(low/neg) counterparts. These data support the hypothesis that NK cells contribute to anti-HCV defense in vivo in the earliest stages of infection, providing innate protection from HCV acquisition.
Golden-Mason
Lucy
L
Department of Medicine, Division of GI/Hepatology, University of Colorado Denver, Aurora, CO, USA.
Cox
Andrea L
AL
Randall
Jessica A
JA
Cheng
Linling
L
Rosen
Hugo R
HR
D019002:CD56 Antigen / Q000032:analysis; D002470:Cell Survival; D005434:Flow Cytometry; D005786:Gene Expression Regulation / Q000276:immunology; D006526:Hepatitis C / Q000453:epidemiology / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D022781:Hepatocytes / Q000166:cytology / Q000473:pathology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000276:immunology*; D055628:Natural Cytotoxicity Triggering Receptor 3 / Q000235:genetics*; D012016:Reference Values; D012307:Risk Factors; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000276:immunology / Q000473:pathology
D019002:CD56 Antigen; D055628:Natural Cytotoxicity Triggering Receptor 3; D007371:Interferon-gamma
Science. 2004 Aug 6;305(5685):872-4
15297676
Hepatology. 2009 Mar;49(3):753-62
19085952
J Virol. 2007 Sep;81(17):9292-8
17553896
Clin Infect Dis. 2005 Apr 1;40(7):951-8
15824985
Eur J Immunol. 2004 Aug;34(8):2313-21
15259029
J Immunol. 1999 Aug 15;163(4):2314-21
10438977
J Exp Med. 2002 Jan 7;195(1):43-9
11781364
J Leukoc Biol. 2004 Dec;76(6):1171-9
15339939
J Hepatol. 2002 Oct;37(4):514-22
12217606
Eur J Immunol. 1999 May;29(5):1656-66
10359120
J Immunol. 2003 Dec 1;171(11):5663-7
14634071
Int J Tissue React. 1993;15(1):11-6
8282480
Hepatol Res. 2005 Aug;32(4):213-7
15905121
Am J Pathol. 2005 Feb;166(2):443-53
15681828
J Immunol. 2009 Aug 15;183(4):2610-21
19635919
Nature. 2005 Aug 18;436(7053):946-52
16107834
J Virol. 2003 Aug;77(15):8299-309
12857899
Cell Mol Immunol. 2008 Dec;5(6):475-8
19118515
J Hepatol. 2002 Jul;37(1):101-8
12076868
Expert Rev Anti Infect Ther. 2006 Oct;4(5):767-80
17140354
Eur J Immunol. 2007 Feb;37(2):445-55
17273991
J Viral Hepat. 2008 Dec;15(12):855-64
18637071
J Exp Med. 2002 Jan 7;195(1):35-41
11781363
Tissue Antigens. 2007 Apr;69 Suppl 1:237-40
17445209
Hepatology. 2009 Dec;50(6):1750-5
19824079
Annu Rev Immunol. 2005;23:225-74
15771571
Nat Immunol. 2005 May;6(5):515-23
15821739
J Virol. 2003 Feb;77(3):2251-7
12525661
Hepatology. 1997 Sep;26(3 Suppl 1):62S-65S
9305666
J Infect Dis. 2007 Apr 15;195(8):1160-8
17357052
J Hepatol. 2010 Feb;52(2):183-90
20015567
Clin Exp Immunol. 1997 Sep;109(3):451-7
9328121
Gut. 2006 Jun;55(6):869-77
16322112
Trends Immunol. 2001 Nov;22(11):633-40
11698225
Gut. 2008 Aug;57(8):1121-8
18372499
Science. 1999 Jul 2;285(5424):26-30
10428695
J Exp Med. 1998 Jun 15;187(12):2065-72
9625766
J Virol. 2005 Oct;79(19):12365-74
16160163
Hepatology. 2006 Mar;43(3):573-80
16496327
J Virol. 2008 Feb;82(4):1827-37
18045940
Annu Rev Immunol. 2001;19:197-223
11244035
J Immunol. 2005 Feb 15;174(4):2160-6
15699147
Curr Opin Microbiol. 1999 Aug;2(4):374-81
10458991